• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Fibrogen Inc CS (NQ: FGEN )

    0.3104 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Fibrogen Inc CS

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    FibroGen's Return on Invested Capital Overview
    Via Benzinga
    FibroGen's Anemia Candidate Fails In Myelodysplastic Syndrome Study
    Via Benzinga
    FibroGen Earnings Preview
    Via Benzinga
    Why did Sarepta Therapeutics Stock Plummet?
    SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
    Via MarketBeat
    Exposures Product Safety
    FibroGen's Return On Capital Employed Insights
    Via Benzinga
    Analyst Ratings for FibroGen
    Via Benzinga
    FibroGen Shares Gain As Analyst Creates Bullish Pitch On Pulmonary Fibrosis Opportunity
    Via Benzinga
    B of A Securities Upgrades FibroGen: Here's What You Need To Know
    Via Benzinga
    Short Volatility Alert: FibroGen, Inc.
    On Tuesday, shares of FibroGen, Inc. (NASDAQ: FGEN) experienced volatile short activity. After the activity, the stock price went down -4.38% to $12.87. The overall sentiment for FGEN has been... 
    Via Benzinga
    Recap: FibroGen Q2 Earnings
      FibroGen (NASDAQ:FGEN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Earnings Scheduled For February 27, 2023
    Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
    Via Benzinga
    Earnings Preview For FibroGen
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
    Via Benzinga
    Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
    U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Tuesday. Here are some big stocks recording losses in today’s session. 
    Via Benzinga
    Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization... 
    Via Benzinga
    FibroGen Earnings Preview
    FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report... 
    Via Benzinga
    7 Unknown Biotech Stocks That Could Rocket in 2023
    Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline. 
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
    Via Benzinga
    Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
    Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
    Via Benzinga
    Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
    Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
    Via Benzinga
    Recap Of Friday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    FibroGen Concludes Dosing In Late-Stage Blood Cell Disorder Study, Sees Top-line Data In H1 2023
    FibroGen, Inc. (NASDAQ: FGEN) has completed patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent... 
    Via Benzinga
    FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Preview: FibroGen's Earnings
    FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report... 
    Via Benzinga
    FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News
    AKBA stock is up big, but the lack of news is concerning considering that Akebia Therapeutics already faces a regulatory setback. 
    Via InvestorPlace
    FibroGen, Inc. (NASDAQ:FGEN) Investor Alert: Investigation over Potential Wrongdoing
    San Diego, CA -- (SBWIRE) -- 06/24/2022 -- An investigation was announced for current long-term investors in shares of FibroGen, Inc. (NASDAQ:FGEN) over potential breaches of fiduciary duties by... 
    Via SBWire
    FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
    From Kahn Swick & Foti, LLC
    Via Business Wire
    103 Biggest Movers From Yesterday
    Gainers 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.